Economic Aspects in the Management of Diabetic Macular Edema in Italy.

ABSTRACT:

Background

Diabetic Macular Edema (DME) is the most common cause of vision loss in diabetic patients. Currently, the Vascular Endothelial Growth Factor inhibitors (anti-VEGFs) are used as the first line of DME treatment and corticosteroid implants are usually used as a second-line treatment. These implants are a safe and effective therapeutic option that can improve the quality of life of DME patients by reducing the intravitreal injections number. We determined the economic impact related to DME, also from the social perspective, and the consequences of the increased use of the dexamethasone implant.

Methods

The analysis compares two scenarios: the first based on the current rate of recourse to the therapeutic alternatives available in the Italian healthcare setting (as is)

SUBMITTER: Calabro GE 

PROVIDER: S-EPMC9353644 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature